TQB6411

TQB6411 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical. Its targets are EGFR and MET. ClinicalTrials.gov describes the intervention as: TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer and oesophageal cancer. The largest, NCT07367529, plans to enrol 465 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.